Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00217763
Status:
UNKNOWN
Last Update Posted:
2007-12-10
First Post:
2005-09-14
Brief Title:
European Study of 3APS in Mild to Moderate Alzheimers Disease Patients
Sponsor:
Bellus Health Inc - a GSK company
Organization:
Bellus Health Inc - a GSK company
Study Overview
Official Title:
A Phase III Study of the Efficacy and Safety of 3APS as Add-on Therapy in Mild to Moderate Alzheimers Disease
Status:
UNKNOWN
Status Verified Date:
2007-12
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this Phase 3 study is to evaluate the efficacy and safety of 3APS as an add-on therapy to most standard medication for Alzheimers disease compared to placebo inactive substance pill in patients with mild to moderate Alzheimers disease
Detailed Description:
Duration of treatment 18 months
3 treatment arms
Placebo and 2 different doses of active drug
3 treatment arms
Placebo and 2 different doses of active drug
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None